Journal
RHEUMATOLOGY
Volume 54, Issue 5, Pages 854-859Publisher
OXFORD UNIV PRESS
DOI: 10.1093/rheumatology/keu418
Keywords
predictors; adequate observational period; long-term efficacy; abatacept; RA; Japanese; multicentre registry system
Categories
Funding
- Mitsubishi Tanabe Pharma Corporation
- Takeda Pharma Corporation
- Eisai Pharma Corporation
- Abbvie
- Bristol-Myers Squibb
- Pfizer
- Chugai Pharma Corporation
- Janssen Pharmaceutical
- Astellas Pharma Corporation
- Abbott Japan Co. Ltd
- Eisai Co. Ltd
- Pfizer Co. Ltd
- Chugai Pharmaceutical Co. Ltd
- Bristol-Myers Squibb Co. Ltd.
- AbbVie Japan Co. Ltd
- Astellas Pharma
- Takeda Pharmaceutical Co. Ltd
- Mitsubishi-Tanabe Pharmaceutical Co. Ltd
- Astellas Pharmaceutical Inc.
- Abbott Japan
- Daiichi Sankyo Company Ltd
- Janssen
- Kaken Pharmaceutical Co. Ltd
- Pfizer Japan Inc.
- Hisamitsu Pharmaceutical Co. Inc.
- Otsuka Pharmaceutical Co. Ltd
- Taisho Toyama Pharmaceutical Co. Ltd
- Janssen Pharmaceutical KK
- Mitsubishi Tanabe Pharmaceutical
- UCB Japan
- Astellas Pharma Inc.
- Chugai Pharmaceutical Co. Ltd.
Ask authors/readers for more resources
Objective. Only a few studies have assessed predictive factors for the long-term efficacy of abatacept. This study aimed to provide clinical evidence of an adequate observational period for predicting low disease activity (LDA) achievement at 52 weeks in RA patients treated with abatacept. Methods. Participants were all patients registered in a Japanese multicentre registry who were treated with abatacept and had at least 52 weeks of follow-up (n = 254). Results. Areas under the receiver operating characteristic curves for the 28-joint count with CRP (DAS28-CRP) at each time point for LDA achievement at 52 weeks were: 0.686 (cut-off score: 4.6) at baseline, 0.780 (3.8) at 4 weeks, 0.875 (3.3) at 12 weeks, and 0.900 (3.0) at 24 weeks. Although patients with a DAS28-CRP score < 3.0 at 24 weeks had the highest proportion of LDA achievement at 52 weeks (79.3%), the proportion for those with a score < 3.3 at 12 weeks was comparable (77.2%, P = 0.697). Proportions were significantly lower in patients with a score < 3.8 at 4 weeks or < 4.6 at baseline. Multivariate logistic regression demonstrated that a DAS28 score of < 3.3 at 12 weeks was an independent strong predictor for LDA at 52 weeks (adjusted odds ratio: 15.2, P < 0.001). Conclusion. Twelve weeks is an adequate observational period to judge the long-term clinical efficacy of abatacept, and is about as early as the period for assessing TNF blockade therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available